Literature DB >> 17344251

Randomised controlled trial of nasal continuous positive airways pressure (CPAP) in bronchiolitis.

Lena P Thia1, Sheila A McKenzie, Tom P Blyth, Caro C Minasian, Wanda J Kozlowska, Siobhan B Carr.   

Abstract

AIMS: To compare continuous positive airways pressure (CPAP) with standard treatment (ST) in the management of bronchiolitis.
METHODS: Children <1 year of age with bronchiolitis and capillary PCO2 >6 kPa were recruited and randomised to CPAP or ST and then crossed over to the alternative treatment after 12 h. ST was intravenous fluids and supplemental oxygen by nasal prongs or face mask. The change in PCO2 was compared between the groups after 12 and 24 h. Secondary outcomes were change in capillary pH, respiratory rate, pulse rate and the need for invasive ventilatory support.
RESULTS: 29 of 31 children completed the study. PCO2 after 12 h fell by 0.92 kPa in children treated with CPAP compared with a rise of 0.04 kPa in those on ST (p<0.015). If CPAP was used first, there was a significantly better reduction in PCO2 than if it was used second. There were no differences in secondary outcome measures. CPAP was well tolerated with no complications identified.
CONCLUSIONS: This study suggests that CPAP compared with ST improves ventilation in children with bronchiolitis and hypercapnoea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344251     DOI: 10.1136/adc.2005.091231

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  43 in total

1.  High flow on the rise-pediatric perspectives on the FLORALI trial.

Authors:  Christophe Milési; Julien Baleine; Julia le Bouhellec; Marti Pons-Odena; Gilles Cambonie
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Acute bronchiolitis: Risk of hyponatraemia.

Authors:  Michael Eisenhut
Journal:  BMJ       Date:  2007-12-01

Review 3.  Acute bronchiolitis.

Authors:  Andrew Bush; Anne H Thomson
Journal:  BMJ       Date:  2007-11-17

4.  CPAP and HFOV: different guises of the same underlying intensive care strategy for supporting RSV bronchiolitis.

Authors:  Robert C Tasker
Journal:  Intensive Care Med       Date:  2008-05-24       Impact factor: 17.440

Review 5.  Bronchiolitis.

Authors:  Thomas Bourke; Michael Shields
Journal:  BMJ Clin Evid       Date:  2011-04-11

6.  Use of Nasal Bubble CPAP in Children with Hypoxemic Clinical Pneumonia-Report from a Resource Limited Set-Up.

Authors:  Muralidharan Jayashree; H B KiranBabu; Sunit Singhi; Karthi Nallasamy
Journal:  J Trop Pediatr       Date:  2015-09-30       Impact factor: 1.165

7.  Comparison of a high-flow humidified nasal cannula to nasal continuous positive airway pressure in children with acute bronchiolitis: experience in a pediatric intensive care unit.

Authors:  Prune Metge; Céline Grimaldi; Sophie Hassid; Laurent Thomachot; Anderson Loundou; Claude Martin; Fabrice Michel
Journal:  Eur J Pediatr       Date:  2014-02-14       Impact factor: 3.183

8.  Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study.

Authors:  Christophe Milési; Julien Baleine; Stefan Matecki; Sabine Durand; Clémentine Combes; Aline Rideau Batista Novais; Gilles Cambonie; Gilles Combonie
Journal:  Intensive Care Med       Date:  2013-03-14       Impact factor: 17.440

9.  Predicting non-invasive ventilation failure in children from the SpO₂/FiO₂ (SF) ratio.

Authors:  Juan Mayordomo-Colunga; Martí Pons; Yolanda López; M José Solana; Corsino Rey; Pablo Martínez-Camblor; Antonio Rodríguez-Núñez; Jesús López-Herce; Alberto Medina; Clara Abadesso; M Angeles García-Teresa; Mirella Gáboli; Milagros García-López; María González-Sánchez; Paula Madurga-Revilla; Amelia González-Calvar; Eider Oñate
Journal:  Intensive Care Med       Date:  2013-03-27       Impact factor: 17.440

10.  The change in management of bronchiolitis in the intensive care unit between 2000 and 2015.

Authors:  Minna Mecklin; Paula Heikkilä; Matti Korppi
Journal:  Eur J Pediatr       Date:  2018-05-15       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.